Celgene Rises After Settling Patent Litigation on Top Drug
This article is for subscribers only.
Celgene Corp. shares jumped after the company said it settled a patent dispute over Revlimid, its top-selling drug, with Natco Pharma Ltd.
Under the settlement, Natco will be able to start selling generic Revlimid in the U.S. in March 2022, but with restrictions on the volume sold, according to a Celgene statement on Tuesday. Starting Jan. 31, 2026, Natco will be able to sell the generic without volume limitations.